Skip to content
Peptigraph home

Tirzepatide and NAD+ Together: What Is Known

Tirzepatide and NAD+ taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[10]GLP-1 & metabolic
Coenzyme (injectable, IV or nasal)CompoundedNAD+Coenzyme sold as an injectable wellness product; a systematic review concluded clinical effectiveness for anti-aging or wellness outcomes remains inconclusive.[11]
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 3 results, 2 Oct 2026).

NAD+ is not FDA approved, and we have no sourced data on combining it with Tirzepatide.
Each component

Side by side

Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.

FieldTirzepatideNAD+
ClassGLP-1 / GIP dual agonistCoenzyme (injectable, IV or nasal)
Also calledtirz, tirze, Mounjaro, ZepboundNAD, nicotinamide adenine dinucleotide
FDA statusFDA approved (Mounjaro, Zepbound)Compounded
WADANot on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.No WADA record in our data
Half-lifeapproximately 5 dayssubcutaneous · FDA label (Mounjaro)[half-life by route]
Evidence strengthHuman RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163[evidence grade]
Human studies we summarised24 human (22 randomized or controlled) of 30 summarised[n]
Typical study doses[dose range]
Named in FDA warning letters, 2026Yes (24 Aug 2026; 31 Mar 2026)Not in the letters we track

A PubMed title and abstract search on 2 Oct 2026 for NAD+ with tirzepatide matched 3 records: two mouse studies and a cost-effectiveness review. None gave people tirzepatide plus NAD+.

Calculated from pubmed query ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); records matched 3; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

In a mouse model of cisplatin kidney injury, the authors report that tirzepatide boosted NAD+ levels through NAMPT, the rate-limiting enzyme for NAD+ synthesis. This is mouse and cell data.[12]

A mouse Parkinson's model found tirzepatide improved mitochondrial structure and raised ATP content in the substantia nigra.[13]

What human NAD+ trials show

A systematic review found oral NR and NMN consistently showed biochemical target engagement in people, but their functional, metabolic and vascular effects varied and were often absent.[11]

The same review found no outcome trials of injected NAD+ itself for anti-ageing or wellness.[11]

Tirzepatide label and compounding

Per the Zepbound label, delayed gastric emptying from tirzepatide may change how well oral medicines taken alongside it are absorbed.[14]

FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed.[15]

Common questions

Can you take NAD+ and tirzepatide together?

No human study has tested the pair. The review of NAD+ evidence calls clinical effectiveness for wellness outcomes inconclusive.[11]

Does tirzepatide raise NAD levels?

Only in mouse kidney-injury work, where the paper reports tirzepatide boosting NAD+ in cisplatin-injured mice. No human measurement was found.[12]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  7. 7Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  8. 8Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  9. 9PubMed search: ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  11. 11NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Ageing research reviews · 2026PMID 41655607Accessed 2 Oct 2026
  12. 12Tirzepatide ameliorates cisplatin-induced acute kidney injury by restoring NAMPT/NAD + homeostasis and enhancing Pink1-Parkin-mediated mitophagy.Biochemical pharmacology · 2026PMID 42114682Accessed 2 Oct 2026
  13. 13GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.International immunopharmacology · 2025PMID 40886502Accessed 2 Oct 2026
  14. 14ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  15. 15Official web pageOfficial web page · web page

Found an error? Report a correction.